Last reviewed · How we verify

Associazione Italiana per lo Studio del Pancreas — Portfolio Competitive Intelligence Brief

Associazione Italiana per lo Studio del Pancreas pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
short-course chemotherapy short-course chemotherapy phase 3
PAXG PAXG phase 3 PD-1 inhibitor PD-1 Oncology
long-course chemotherapy long-course chemotherapy phase 3 Chemotherapy Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
  2. Sun Yat-sen University · 2 shared drug classes
  3. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 2 shared drug classes
  4. ATGC Co., Ltd. · 1 shared drug class
  5. Akeso · 1 shared drug class
  6. Amgen · 1 shared drug class
  7. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  8. Asahi Kasei Pharma Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Associazione Italiana per lo Studio del Pancreas:

Cite this brief

Drug Landscape (2026). Associazione Italiana per lo Studio del Pancreas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/associazione-italiana-per-lo-studio-del-pancreas. Accessed 2026-05-17.

Related